Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 8/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096598 | 1.00 | ATM (0.43) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL15434331 | 0.97 | ATM (0.42) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL31232348 | 0.93 | ATM (0.45) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL5220048 | 0.93 | ATM (0.45) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL12090912 | 0.89 | CTSK (0.39) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL31048296 | 0.89 | ATM (0.45) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL7842461 | 0.89 | ATM (0.46) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL5548155 | 0.89 | ATM (0.46) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL30133471 | 0.89 | ATM (0.46) | ATMCTSKPPARACTSSPPARG | |
| SCHEMBL15434434 | 0.88 | MAPT (0.48) | ATMCTSKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112351778-B | Fused tricyclic heterocycles and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| CN-112351778-A | Fused tricyclic heterocycles and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2021-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | ATM 1218/4885CTSK 353/4885PPARA 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.